Correction to: All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits.

Wu, Huai-Liang; Luo, Zi-Yin; He, Zong-Lin; Gong, Yue; Mo, Miao; Ming, Wai-Kit; Liu, Guang-Yu

Wu, Huai-Liang; Luo, Zi-Yin; He, Zong-Lin; Gong, Yue; Mo, Miao; Ming, Wai-Kit; Liu, Guang-Yu.

Afiliação

Wu HL; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Luo ZY; Department of Otorhinolaryngology Head and Neck Surgery, The Sixth Affiliated Hospital of Sun Yatsen University, Guangzhou, China.
He ZL; Division of Life Science, The Hong Kong University of Science and Technology, Hong Kong SAR, China.
Gong Y; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Mo M; Department of Cancer Prevention, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Ming WK; Department of Infectious Diseases and Public Health, Jockey Club College of Veterinary Medicine and Life Science, City University of Hong Kong, Hong Kong SAR, China.
Liu GY; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Department of Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. liugy688@163.com.

Br J Cancer ; 128(4): 704, 2023 Feb.

Article em En | MEDLINE | ID: mdl-36717677

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Revista: Br J Cancer Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google